Clinical Unit for Research Trials in Skin, Massachusetts General Hospital, Boston, Massachusetts 02139, USA.
J Am Acad Dermatol. 2010 Jul;63(1):52-62. doi: 10.1016/j.jaad.2009.07.052. Epub 2010 May 21.
Comparative efficacy of the multiple treatments containing benzoyl peroxide (BPO) and clindamycin (CL) is not established.
We compared the efficacy of topical 5% BPO, 1% to 1.2% CL, 5% BPO with salicylic acid (SA) preparation, and combination BPO/CL in acne lesion reduction.
A meta-analysis was conducted using the Cochrane collaboration guidelines in accordance with the PRISMA statement.
A total of 23 studies including 7309 patients were used in the meta-analysis. At 2 to 4 weeks, 5% BPO + SA had statistically greater percent lesion reductions over other groups (weighted mean inflammatory lesion reduction: BPO = 33.4%, CL = 21.5%, BPO + SA = 55.2%, BPO/CL = 40.7%, placebo = 7.3%; weighted mean noninflammatory lesion reduction: BPO = 19.1%, CL = 10.0%, BPO + SA = 42.7%, BPO/CL = 26.2%, placebo = 6.7%). At 10- to 12-week end points, 5% BPO + SA and BPO/CL were similar, with overlapping confidence intervals (weighted mean inflammatory lesion reduction: BPO = 43.7%, CL = 45.9%, BPO + SA = 51.8%, BPO/CL = 55.6%, placebo = 26.8%; weighted mean noninflammatory lesion reduction: BPO = 30.9%, CL = 32.6%, BPO + SA = 47.8%, BPO/CL = 40.3%, placebo = 17.0%).
Trial heterogeneity, publication bias, and deficits in the reporting of individual primary studies may affect results.
At early time points, 5% BPO + SA had the best profile. BPO/CL was only incrementally better than BPO alone but was superior to CL alone. At later time points, 5% BPO + SA was similar to BPO/CL.
目前尚无关于过氧化苯甲酰(BPO)和克林霉素(CL)多种疗法疗效的比较。
我们比较了外用 5% BPO、1%至 1.2% CL、5%BPO 与水杨酸(SA)制剂以及 BPO/CL 联合治疗在减少痤疮皮损方面的疗效。
我们使用 Cochrane 协作组指南并根据 PRISMA 声明进行了荟萃分析。
共有 23 项研究,纳入了 7309 例患者,用于荟萃分析。在 2 至 4 周时,5%BPO+SA 在减少炎症性皮损方面的疗效明显优于其他组(加权平均炎症性皮损减少:BPO=33.4%,CL=21.5%,BPO+SA=55.2%,BPO/CL=40.7%,安慰剂=7.3%;加权平均非炎症性皮损减少:BPO=19.1%,CL=10.0%,BPO+SA=42.7%,BPO/CL=26.2%,安慰剂=6.7%)。在 10 至 12 周的终点,5%BPO+SA 和 BPO/CL 相似,置信区间重叠(加权平均炎症性皮损减少:BPO=43.7%,CL=45.9%,BPO+SA=51.8%,BPO/CL=55.6%,安慰剂=26.8%;加权平均非炎症性皮损减少:BPO=30.9%,CL=32.6%,BPO+SA=47.8%,BPO/CL=40.3%,安慰剂=17.0%)。
试验异质性、发表偏倚以及个别原始研究报告的不足可能会影响结果。
在早期,5%BPO+SA 的疗效最佳。BPO/CL 仅比单独使用 BPO 略有改善,但优于单独使用 CL。在后期,5%BPO+SA 与 BPO/CL 相似。